CONTEXT THERAPEUTICS INC (CNTX)

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development...

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Context Therapeutics (NASDAQ:CNTX) just reported results for the fourth quarter...

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash...

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash...

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning!

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company...

Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update

Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76.

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June...

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Context Therapeutics to Participate in Two August 2023 Investor Conferences

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company...

Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash...

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Context Therapeutics to Participate in Two April 2023 Investor Conferences

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!